Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults-Reference-Cited by-同舟云学术

Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults

Published:2024-08-13 Issue:3 Volume:103 Page:
ISSN:0028-3878
Container-title:Neurology
language:en
Short-container-title:Neurology

Author:

Deschamps Romain¹^ORCID,Guillaume Jessica¹,Ciron Jonathan¹^ORCID,Audoin Bertrand¹^ORCID,Ruet Aurélie¹^ORCID,Maillart Elisabeth¹^ORCID,Pique Julie¹^ORCID,Benyahya Lakhdar¹,Laplaud David A.¹^ORCID,Michel Laure¹^ORCID,Collongues Nicolas¹^ORCID,Cohen Mikael¹^ORCID,Ayrignac Xavier¹^ORCID,Thouvenot Eric¹^ORCID,Zephir Helene¹^ORCID,Bourre Bertrand¹^ORCID,Froment Tilikete Caroline¹^ORCID,Moreau Thibault¹^ORCID,Cantagrel Paul¹,Kerschen Philippe¹^ORCID,Cabasson Sebastien¹,Maubeuge Nicolas¹,Hankiewicz Karolina¹,Nifle Chantal¹,Berger Eric¹^ORCID,Megherbi Hana¹,Magy Laurent¹^ORCID,Klapczynski Frederic¹,Sarov Riviere Mariana¹,Giannesini Claire¹,Hamelin Lorraine¹,Giroux Marianne¹,Branger Pierre¹^ORCID,Maurousset Aude¹^ORCID,Mathey Guillaume¹,Moulin Maximilien¹^ORCID,Mélé Nicolas¹,Papeix Caroline¹^ORCID,Marignier Romain¹^ORCID,

Affiliation:

1. From the Department of Neurology (R.D.); Clinical Research Department (J.G.), Rothschild Foundation Hospital, Paris; Department of Neurology (J.C.), University Hospital of Toulouse; Department of Neurology (B.A.), Pôle de Neurosciences Cliniques, APHM, Aix Marseille University, Hôpital de la Timone; Department of Neurology (A.R.), University Hospital of Bordeaux; Centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM) (E.M., C.G.), Department of Neurology, AP-HP,...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Link

https://www.neurology.org/doi/pdfdirect/10.1212/WNL.0000000000209624

Reference27 articles.

1. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults

2. Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease in the United Kingdom

3. Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

4. Do Early Relapses Predict the Risk of Long‐Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD?

5. Clinical feature and disease outcome in patients with myelin oligodendrocyte glycoprotein antibody-associated disorder: a Chinese study

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mr. Machiavelli's Choice for Treatment of MOG Antibody Disease: Do the benefits of long-term corticosteroids justify the means?;Multiple Sclerosis and Related Disorders;2024-09